Narita, Aya
Koto, Yuta
Noto, Shinichi
Okada, Masafumi
Ono, Midori
Baba, Terumi
Sagara, Rieko
Sakai, Norio http://orcid.org/0000-0003-3374-6709
Funding for this research was provided by:
Takeda Pharmaceutical Company
Article History
Received: 12 April 2023
Accepted: 13 December 2023
First Online: 5 January 2024
Declarations
:
: The protocol and informed consent form were approved on January 13, 2021 (No. 20342) by Osaka University Clinical Research Review Committee. Written informed consent was obtained by patients or their proxies. This study was conducted in accordance with the protocol, the Declaration of Helsinki, Guidelines for Good Pharmacoepidemiology Practices by the International Society of Pharmacoepidemiology, and Japanese regulations.
: Not applicable.
: AN, YK, and NS have received research funding from and have served as consultants and on speakers’ bureaus for Takeda Pharmaceutical Company Limited (hereafter Takeda). SN has served as a consultant for Takeda. M Okada is a former employee of IQVIA Solutions Japan K.K. M Ono and RS are employees, and TB is a former employee, of Takeda. M Ono is a stockholder of Takeda.